A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell Malignancies
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 17 Jan 2023 Planned End Date changed from 27 Oct 2022 to 13 Dec 2024.
- 17 Jan 2023 Planned primary completion date changed from 27 Oct 2022 to 13 Dec 2024.
- 10 Aug 2021 Planned End Date changed from 31 Jul 2023 to 27 Oct 2022.